Perpetual Ltd Sells 319,632 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Perpetual Ltd lowered its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,279,620 shares of the company's stock after selling 319,632 shares during the period. Perpetual Ltd owned 0.48% of Autolus Therapeutics worth $3,007,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics in the second quarter worth approximately $43,000. Arkadios Wealth Advisors bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $47,000. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the third quarter worth $51,000. Avanza Fonder AB bought a new position in Autolus Therapeutics during the fourth quarter worth $75,000. Finally, Herbst Group LLC acquired a new position in Autolus Therapeutics in the third quarter valued at $91,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Trading Down 1.4 %

NASDAQ AUTL traded down $0.03 during mid-day trading on Wednesday, hitting $2.16. The company's stock had a trading volume of 1,333,264 shares, compared to its average volume of 1,104,659. The firm has a market capitalization of $574.75 million, a price-to-earnings ratio of -1.79 and a beta of 2.05. The company's 50 day simple moving average is $2.63 and its 200 day simple moving average is $3.53. Autolus Therapeutics plc has a twelve month low of $2.07 and a twelve month high of $7.37.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm earned ($0.26) EPS. As a group, research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on AUTL shares. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.